|
内容記述 |
Uterine serous carcinoma (USC) is a rare aggressive type 2 endometrial carcinoma and often has peritoneal metastasis even in early stage Trastuzumab, the anti-HER2 antibody, has been clinically used against HER2 positive USC, however the antibody treatment resistance has been remain as an issue.Targeted alpha therapy (TAT) is useful for metastasis and has high potential to overcome antibody treatment resistance. The alpha-particle effectively kill the cells by inducing irreparable DNA damages, which is different from how trastuzumab works. Astatine 211 (At-211) is one of the attractive α-particle emitters. We have demonstrated experimental TAT using [At-211]-trastuzumab to HER2 positive USCPM mouse model to investigate the therapeutic efficacy and toxicity. We will discuss the potential of TAT as a novel therapeutic option for antibody treatment resistant PM of HER2 positive USC. |
